Drugs that contain Crizotinib

1. List of Xalkori drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785632 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Mar, 2025

(2 years from now)

US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(2 years from now)

US7858643 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Oct, 2029

(6 years from now)

US8217057 PF PRISM CV Polymorphs of a c-MET/HGFR inhibitor
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7825137 PF PRISM CV Method of treating abnormal cell growth
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 14, 2028
New Indication (I) Jul 14, 2025

Market Authorisation Date: 26 August, 2011

Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; Treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in